Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease. The decision comes on the experimental drug RP-A501, resulting in a serious adverse event that led to a patient’s demise. Likewise, Leerink Partners downgraded the stock to ‘Market Perform’ from an ‘Outperform’ and cut the price target to $8 from $37 on May 28.
A successful investor with a portfolio including Finance Receivables, biotechnology, and medical device investments.
The downgrade comes on Rocket Pharmaceutical recording its biggest slump in the market. The stock lost more than 50% in market value after the US Food and Drug Administration placed a hold on phase 2 trials for the candidate drug. Rocket Pharmaceuticals’ webcast disclosed a serious adverse event (SAE), where a patient succumbed to acute systemic infection, leading to a clinical hold on the Phase 2 Danon disease program. It is a rare hereditary condition that results in gradual muscular weakening and damage to the heart muscle.
Leerink Partners insists the company needs to address safety uncertainties and resolve clinical hold for a favorable rating. In addition, Leerink Partners insists that Rocket Pharmaceuticals faces an uphill task of re-establishing investor confidence. That’s partly because the company needs to meet revised timelines for clinical programs, including LAD-I, Danon, and FA. Following the significant blow on the Danon Disease treatment, Rocket Pharmaceuticals has imploded to all-time lows. The stock is down by about 80% year to date.
Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to developing gene therapies for rare and life-threatening diseases in the U.S., advancing adeno-associated viral (AAV) and lentiviral (LV) programs to target cardiac and immune disorders. Its AAV pipeline includes treatments for Danon disease (RP-A501, Phase 2), Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601, Phase 1), and BAG3 Dilated Cardiomyopathy (preclinical). At the same time, its LV platform develops therapies for Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102), and Pyruvate Kinase Deficiency (RP-L301), addressing critical immune and blood disorders.
While we acknowledge the potential of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RCKT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None.
Hedge Fund Resource Center